Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 85 entries
Sorted by: Best Match Show Resources per page
Does the use of primary continuous positive airway pressure reduce the need for intubation and mechanical ventilation in infants ≤32 weeks' gestation?.

Paediatrics & child health

Yee WH, Scotland J, Pham Y, Finch R.
PMID: 23204903
Paediatr Child Health. 2011 Dec;16(10):633-7.

BACKGROUND: Ventilator-induced lung injury is a recognized risk factor for bronchopulmonary dysplasia.OBJECTIVE: To determine whether primary continuous positive airway pressure (CPAP), defined as CPAP without previous endotracheal intubation for any indication, can reduce the need for intubation and mechanical...

Cite
Yee WH, Scotland J, Pham Y, et al. Does the use of primary continuous positive airway pressure reduce the need for intubation and mechanical ventilation in infants ≤32 weeks' gestation?. Paediatr Child Health. 2011;16(10):633-7
Yee, W. H., Scotland, J., Pham, Y., Finch, R. (2011). Does the use of primary continuous positive airway pressure reduce the need for intubation and mechanical ventilation in infants ≤32 weeks' gestation?. Paediatrics & child health, 16(10), 633-7.
Yee, Wendy H, et al. "Does the use of primary continuous positive airway pressure reduce the need for intubation and mechanical ventilation in infants ≤32 weeks' gestation?." Paediatrics & child health vol. 16,10 (2011): 633-7.
Yee WH, Scotland J, Pham Y, Finch R. Does the use of primary continuous positive airway pressure reduce the need for intubation and mechanical ventilation in infants ≤32 weeks' gestation?. Paediatr Child Health. 2011 Dec;16(10):633-7. PMID: 23204903; PMCID: PMC3225473.
Copy Download .nbib Format: NLM
Value of immunohistochemical detection of noncollagenous proteins of bone for the diagnosis of bone tumours.

International journal of oncology

Serra M, Scotlandi K, Sollazzo M, Sarti M, Maurici D, Benini S, Picci P, Bertoni F, Baldini N.
PMID: 21541509
Int J Oncol. 1996 Aug;9(2):257-61.

The expression of osteonectin, osteopontin, bone sialoprotein, and osteocalcin was evaluated by immunohistochemistry in 57 cases of osteoid-forming and non-osteoid-forming bone tumours using specific polyclonal antibodies and the avidin-biotin peroxidase complex method. A positive immunostaining was found in all...

Cite
Serra M, Scotlandi K, Sollazzo M, et al. Value of immunohistochemical detection of noncollagenous proteins of bone for the diagnosis of bone tumours. Int J Oncol. 1996;9(2):257-61
Serra, M., Scotlandi, K., Sollazzo, M., Sarti, M., Maurici, D., Benini, S., Picci, P., Bertoni, F., & Baldini, N. (1996). Value of immunohistochemical detection of noncollagenous proteins of bone for the diagnosis of bone tumours. International journal of oncology, 9(2), 257-61.
Serra, M, et al. "Value of immunohistochemical detection of noncollagenous proteins of bone for the diagnosis of bone tumours." International journal of oncology vol. 9,2 (1996): 257-61.
Serra M, Scotlandi K, Sollazzo M, Sarti M, Maurici D, Benini S, Picci P, Bertoni F, Baldini N. Value of immunohistochemical detection of noncollagenous proteins of bone for the diagnosis of bone tumours. Int J Oncol. 1996 Aug;9(2):257-61. PMID: 21541509.
Copy Download .nbib Format: NLM
Educational barriers of nurses caring for sick and at-risk infants in India.

International nursing review

Campbell-Yeo M, Deorari A, McMillan DD, Singhal N, Vatsa M, Aylward D, Scotland J, Kumar P, Joshi M, Kalyan G, Dol J.
PMID: 25131708
Int Nurs Rev. 2014 Sep;61(3):398-405. doi: 10.1111/inr.12121. Epub 2014 Aug 08.

AIM: To gain ideas and information from healthcare providers to optimize the education and clinical practices of nurses caring for sick or at-risk newborns in India.BACKGROUND: Improving infant survival has been identified as a Millennium Development Goals; however, India...

Cite
Campbell-Yeo M, Deorari A, McMillan DD, et al. Educational barriers of nurses caring for sick and at-risk infants in India. Int Nurs Rev. 2014;61(3):398-405doi: 10.1111/inr.12121.
Campbell-Yeo, M., Deorari, A., McMillan, D. D., Singhal, N., Vatsa, M., Aylward, D., Scotland, J., Kumar, P., Joshi, M., Kalyan, G., & Dol, J. (2014). Educational barriers of nurses caring for sick and at-risk infants in India. International nursing review, 61(3), 398-405. https://doi.org/10.1111/inr.12121
Campbell-Yeo, M, et al. "Educational barriers of nurses caring for sick and at-risk infants in India." International nursing review vol. 61,3 (2014): 398-405. doi: https://doi.org/10.1111/inr.12121
Campbell-Yeo M, Deorari A, McMillan DD, Singhal N, Vatsa M, Aylward D, Scotland J, Kumar P, Joshi M, Kalyan G, Dol J. Educational barriers of nurses caring for sick and at-risk infants in India. Int Nurs Rev. 2014 Sep;61(3):398-405. doi: 10.1111/inr.12121. Epub 2014 Aug 08. PMID: 25131708.
Copy Download .nbib Format: NLM
The first European interdisciplinary ewing sarcoma research summit.

Frontiers in oncology

Kovar H, Alonso J, Aman P, Aryee DN, Ban J, Burchill SA, Burdach S, De Alava E, Delattre O, Dirksen U, Fourtouna A, Fulda S, Helman LJ, Herrero-Martin D, Hogendoorn PC, Kontny U, Lawlor ER, Lessnick SL, Llombart-Bosch A, Metzler M, Moriggl R, Niedan S, Potratz J, Redini F, Richter GH, Riedmann LT, Rossig C, Schäfer BW, Schwentner R, Scotlandi K, Sorensen PH, Staege MS, Tirode F, Toretsky J, Ventura S, Eggert A, Ladenstein R.
PMID: 22662320
Front Oncol. 2012 May 29;2:54. doi: 10.3389/fonc.2012.00054. eCollection 2012.

The European Network for Cancer Research in Children and Adolescents (ENCCA) provides an interaction platform for stakeholders in research and care of children with cancer. Among ENCCA objectives is the establishment of biology-based prioritization mechanisms for the selection of...

Cite
Kovar H, Alonso J, Aman P, et al. The first European interdisciplinary ewing sarcoma research summit. Front Oncol. 2012;2:54doi: 10.3389/fonc.2012.00054.
Kovar, H., Alonso, J., Aman, P., Aryee, D. N., Ban, J., Burchill, S. A., Burdach, S., De Alava, E., Delattre, O., Dirksen, U., Fourtouna, A., Fulda, S., Helman, L. J., Herrero-Martin, D., Hogendoorn, P. C., Kontny, U., Lawlor, E. R., Lessnick, S. L., Llombart-Bosch, A., Metzler, M., Moriggl, R., Niedan, S., Potratz, J., Redini, F., Richter, G. H., Riedmann, L. T., Rossig, C., Schäfer, B. W., Schwentner, R., Scotlandi, K., Sorensen, P. H., Staege, M. S., Tirode, F., Toretsky, J., Ventura, S., Eggert, A., & Ladenstein, R. (2012). The first European interdisciplinary ewing sarcoma research summit. Frontiers in oncology, 254. https://doi.org/10.3389/fonc.2012.00054
Kovar, Heinrich, et al. "The first European interdisciplinary ewing sarcoma research summit." Frontiers in oncology vol. 2 (2012): 54. doi: https://doi.org/10.3389/fonc.2012.00054
Kovar H, Alonso J, Aman P, Aryee DN, Ban J, Burchill SA, Burdach S, De Alava E, Delattre O, Dirksen U, Fourtouna A, Fulda S, Helman LJ, Herrero-Martin D, Hogendoorn PC, Kontny U, Lawlor ER, Lessnick SL, Llombart-Bosch A, Metzler M, Moriggl R, Niedan S, Potratz J, Redini F, Richter GH, Riedmann LT, Rossig C, Schäfer BW, Schwentner R, Scotlandi K, Sorensen PH, Staege MS, Tirode F, Toretsky J, Ventura S, Eggert A, Ladenstein R. The first European interdisciplinary ewing sarcoma research summit. Front Oncol. 2012 May 29;2:54. doi: 10.3389/fonc.2012.00054. eCollection 2012. PMID: 22662320; PMCID: PMC3361960.
Copy Download .nbib Format: NLM
CD99: A Cell Surface Protein with an Oncojanus Role in Tumors.

Genes

Manara MC, Pasello M, Scotlandi K.
PMID: 29534016
Genes (Basel). 2018 Mar 13;9(3). doi: 10.3390/genes9030159.

The cell surface molecule CD99 has gained interest because of its involvement in regulating cell differentiation and adhesion/migration of immune and tumor cells. However, the molecule plays an intriguing and dual role in different cell types. In particular, it...

Cite
Manara MC, Pasello M, Scotlandi K. CD99: A Cell Surface Protein with an Oncojanus Role in Tumors. Genes (Basel). 2018;9(3)doi: 10.3390/genes9030159.
Manara, M. C., Pasello, M., & Scotlandi, K. (2018). CD99: A Cell Surface Protein with an Oncojanus Role in Tumors. Genes, 9(3), . https://doi.org/10.3390/genes9030159
Manara, Maria Cristina, et al. "CD99: A Cell Surface Protein with an Oncojanus Role in Tumors." Genes vol. 9,3 (2018). doi: https://doi.org/10.3390/genes9030159
Manara MC, Pasello M, Scotlandi K. CD99: A Cell Surface Protein with an Oncojanus Role in Tumors. Genes (Basel). 2018 Mar 13;9(3). doi: 10.3390/genes9030159. PMID: 29534016; PMCID: PMC5867880.
Copy Download .nbib Format: NLM
Correction: Pedigree- and SNP-Associated Genetics and Recent Environment are the Major Contributors to Anthropometric and Cardiometabolic Trait Variation.

PLoS genetics

Xia C, Amador C, Huffman J, Trochet H, Campbell A, Porteous D, Scotland G, Hastie ND, Hayward C, Vitart V, Navarro P, Haley CS.
PMID: 28196069
PLoS Genet. 2017 Feb 14;13(2):e1006608. doi: 10.1371/journal.pgen.1006608. eCollection 2017 Feb.

[This corrects the article DOI: 10.1371/journal.pgen.1005804.].

Cite
Xia C, Amador C, Huffman J, et al. Correction: Pedigree- and SNP-Associated Genetics and Recent Environment are the Major Contributors to Anthropometric and Cardiometabolic Trait Variation. PLoS Genet. 2017;13(2):e1006608doi: 10.1371/journal.pgen.1006608.
Xia, C., Amador, C., Huffman, J., Trochet, H., Campbell, A., Porteous, D., Scotland, G., Hastie, N. D., Hayward, C., Vitart, V., Navarro, P., & Haley, C. S. (2017). Correction: Pedigree- and SNP-Associated Genetics and Recent Environment are the Major Contributors to Anthropometric and Cardiometabolic Trait Variation. PLoS genetics, 13(2), e1006608. https://doi.org/10.1371/journal.pgen.1006608
Xia, Charley, et al. "Correction: Pedigree- and SNP-Associated Genetics and Recent Environment are the Major Contributors to Anthropometric and Cardiometabolic Trait Variation." PLoS genetics vol. 13,2 (2017): e1006608. doi: https://doi.org/10.1371/journal.pgen.1006608
Xia C, Amador C, Huffman J, Trochet H, Campbell A, Porteous D, Scotland G, Hastie ND, Hayward C, Vitart V, Navarro P, Haley CS. Correction: Pedigree- and SNP-Associated Genetics and Recent Environment are the Major Contributors to Anthropometric and Cardiometabolic Trait Variation. PLoS Genet. 2017 Feb 14;13(2):e1006608. doi: 10.1371/journal.pgen.1006608. eCollection 2017 Feb. PMID: 28196069; PMCID: PMC5308822.
Copy Download .nbib Format: NLM
Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1.

Oncotarget

Palmerini E, Agostinelli C, Picci P, Pileri S, Marafioti T, Lollini PL, Scotlandi K, Longhi A, Benassi MS, Ferrari S.
PMID: 29340095
Oncotarget. 2017 Dec 04;8(67):111836-111846. doi: 10.18632/oncotarget.22912. eCollection 2017 Dec 19.

BACKGROUND: We hypothesized that immune-infiltrates were associated with superior survival, and examined a primary osteosarcoma tissue microarrays (TMAs) to test this hypothesis.METHODS: 129 patients (pts) with localized osteosarcoma treated within protocol ISG-OS1 were included in the study. Clinical characteristics,...

Cite
Palmerini E, Agostinelli C, Picci P, et al. Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1. Oncotarget. 2017;8(67):111836-111846doi: 10.18632/oncotarget.22912.
Palmerini, E., Agostinelli, C., Picci, P., Pileri, S., Marafioti, T., Lollini, P. L., Scotlandi, K., Longhi, A., Benassi, M. S., & Ferrari, S. (2017). Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1. Oncotarget, 8(67), 111836-111846. https://doi.org/10.18632/oncotarget.22912
Palmerini, Emanuela, et al. "Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1." Oncotarget vol. 8,67 (2017): 111836-111846. doi: https://doi.org/10.18632/oncotarget.22912
Palmerini E, Agostinelli C, Picci P, Pileri S, Marafioti T, Lollini PL, Scotlandi K, Longhi A, Benassi MS, Ferrari S. Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1. Oncotarget. 2017 Dec 04;8(67):111836-111846. doi: 10.18632/oncotarget.22912. eCollection 2017 Dec 19. PMID: 29340095; PMCID: PMC5762363.
Copy Download .nbib Format: NLM
Correction: Adherence and Satisfaction of Smartphone- and Smartwatch-Based Remote Active Testing and Passive Monitoring in People With Multiple Sclerosis: Nonrandomized Interventional Feasibility Study.

Journal of medical Internet research

Midaglia L, Mulero P, Montalban X, Graves J, Hauser SL, Julian L, Baker M, Schadrack J, Gossens C, Scotland A, Lipsmeier F, van Beek J, Bernasconi C, Belachew S, Lindemann M.
PMID: 31596725
J Med Internet Res. 2019 Oct 08;21(10):e16287. doi: 10.2196/16287.

[This corrects the article DOI: 10.2196/14863.].

Cite
Midaglia L, Mulero P, Montalban X, et al. Correction: Adherence and Satisfaction of Smartphone- and Smartwatch-Based Remote Active Testing and Passive Monitoring in People With Multiple Sclerosis: Nonrandomized Interventional Feasibility Study. J Med Internet Res. 2019;21(10):e16287doi: 10.2196/16287.
Midaglia, L., Mulero, P., Montalban, X., Graves, J., Hauser, S. L., Julian, L., Baker, M., Schadrack, J., Gossens, C., Scotland, A., Lipsmeier, F., van Beek, J., Bernasconi, C., Belachew, S., & Lindemann, M. (2019). Correction: Adherence and Satisfaction of Smartphone- and Smartwatch-Based Remote Active Testing and Passive Monitoring in People With Multiple Sclerosis: Nonrandomized Interventional Feasibility Study. Journal of medical Internet research, 21(10), e16287. https://doi.org/10.2196/16287
Midaglia, Luciana, et al. "Correction: Adherence and Satisfaction of Smartphone- and Smartwatch-Based Remote Active Testing and Passive Monitoring in People With Multiple Sclerosis: Nonrandomized Interventional Feasibility Study." Journal of medical Internet research vol. 21,10 (2019): e16287. doi: https://doi.org/10.2196/16287
Midaglia L, Mulero P, Montalban X, Graves J, Hauser SL, Julian L, Baker M, Schadrack J, Gossens C, Scotland A, Lipsmeier F, van Beek J, Bernasconi C, Belachew S, Lindemann M. Correction: Adherence and Satisfaction of Smartphone- and Smartwatch-Based Remote Active Testing and Passive Monitoring in People With Multiple Sclerosis: Nonrandomized Interventional Feasibility Study. J Med Internet Res. 2019 Oct 08;21(10):e16287. doi: 10.2196/16287. PMID: 31596725; PMCID: PMC6914226.
Copy Download .nbib Format: NLM
Consensus Statement on Urinary Stone Treatment During A Pandemic: A Delphi Process from the Endourological Society TOWER Research Initiative.

Journal of endourology

Scotland K, Tailly T, Chew BH, Bhojani N, Smith RD.
PMID: 35019782
J Endourol. 2022 Jan 12; doi: 10.1089/end.2021.0477. Epub 2022 Jan 12.

INTRODUCTION: The COVID-19 pandemic has had a significant impact on the care of patients with urolithiasis. Recommendations and prioritization of endourologic surgical procedures vary among regions and a comprehensive overall international directive is needed. We used the Delphi method...

Cite
Scotland K, Tailly T, Chew BH, et al. Consensus Statement on Urinary Stone Treatment During A Pandemic: A Delphi Process from the Endourological Society TOWER Research Initiative. J Endourol. 2022;doi: 10.1089/end.2021.0477.
Scotland, K., Tailly, T., Chew, B. H., Bhojani, N., & Smith, R. D. (2022). Consensus Statement on Urinary Stone Treatment During A Pandemic: A Delphi Process from the Endourological Society TOWER Research Initiative. Journal of endourology, . https://doi.org/10.1089/end.2021.0477
Scotland, Kymora, et al. "Consensus Statement on Urinary Stone Treatment During A Pandemic: A Delphi Process from the Endourological Society TOWER Research Initiative." Journal of endourology vol. (2022). doi: https://doi.org/10.1089/end.2021.0477
Scotland K, Tailly T, Chew BH, Bhojani N, Smith RD. Consensus Statement on Urinary Stone Treatment During A Pandemic: A Delphi Process from the Endourological Society TOWER Research Initiative. J Endourol. 2022 Jan 12; doi: 10.1089/end.2021.0477. Epub 2022 Jan 12. PMID: 35019782.
Copy Download .nbib Format: NLM
Cost-effectiveness and value of information analysis of NephroCheck and NGAL tests compared to standard care for the diagnosis of acute kidney injury.

BMC nephrology

Jacobsen E, Sawhney S, Brazzelli M, Aucott L, Scotland G, Aceves-Martins M, Robertson C, Imamura M, Poobalan A, Manson P, Kaye C, Boyers D.
PMID: 34852765
BMC Nephrol. 2021 Dec 01;22(1):399. doi: 10.1186/s12882-021-02610-9.

BACKGROUND: Early and accurate acute kidney injury (AKI) detection may improve patient outcomes and reduce health service costs. This study evaluates the diagnostic accuracy and cost-effectiveness of NephroCheck and NGAL (urine and plasma) biomarker tests used alongside standard care,...

Cite
Jacobsen E, Sawhney S, Brazzelli M, et al. Cost-effectiveness and value of information analysis of NephroCheck and NGAL tests compared to standard care for the diagnosis of acute kidney injury. BMC Nephrol. 2021;22(1):399doi: 10.1186/s12882-021-02610-9.
Jacobsen, E., Sawhney, S., Brazzelli, M., Aucott, L., Scotland, G., Aceves-Martins, M., Robertson, C., Imamura, M., Poobalan, A., Manson, P., Kaye, C., & Boyers, D. (2021). Cost-effectiveness and value of information analysis of NephroCheck and NGAL tests compared to standard care for the diagnosis of acute kidney injury. BMC nephrology, 22(1), 399. https://doi.org/10.1186/s12882-021-02610-9
Jacobsen, Elisabet, et al. "Cost-effectiveness and value of information analysis of NephroCheck and NGAL tests compared to standard care for the diagnosis of acute kidney injury." BMC nephrology vol. 22,1 (2021): 399. doi: https://doi.org/10.1186/s12882-021-02610-9
Jacobsen E, Sawhney S, Brazzelli M, Aucott L, Scotland G, Aceves-Martins M, Robertson C, Imamura M, Poobalan A, Manson P, Kaye C, Boyers D. Cost-effectiveness and value of information analysis of NephroCheck and NGAL tests compared to standard care for the diagnosis of acute kidney injury. BMC Nephrol. 2021 Dec 01;22(1):399. doi: 10.1186/s12882-021-02610-9. PMID: 34852765; PMCID: PMC8638090.
Copy Download .nbib Format: NLM
Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma.

Nature communications

Zoumpoulidou G, Alvarez-Mendoza C, Mancusi C, Ahmed RM, Denman M, Steele CD, Tarabichi M, Roy E, Davies LR, Manji J, Cristalli C, Scotlandi K, Pillay N, Strauss SJ, Mittnacht S.
PMID: 34862364
Nat Commun. 2021 Dec 03;12(1):7064. doi: 10.1038/s41467-021-27291-8.

Loss-of-function mutations in the RB1 tumour suppressor are key drivers in cancer, including osteosarcoma. RB1 loss-of-function compromises genome-maintenance and hence could yield vulnerability to therapeutics targeting such processes. Here we demonstrate selective hypersensitivity to clinically-approved inhibitors of Poly-ADP-Polymerase1,2 inhibitors...

Cite
Zoumpoulidou G, Alvarez-Mendoza C, Mancusi C, et al. Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma. Nat Commun. 2021;12(1):7064doi: 10.1038/s41467-021-27291-8.
Zoumpoulidou, G., Alvarez-Mendoza, C., Mancusi, C., Ahmed, R. M., Denman, M., Steele, C. D., Tarabichi, M., Roy, E., Davies, L. R., Manji, J., Cristalli, C., Scotlandi, K., Pillay, N., Strauss, S. J., & Mittnacht, S. (2021). Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma. Nature communications, 12(1), 7064. https://doi.org/10.1038/s41467-021-27291-8
Zoumpoulidou, Georgia, et al. "Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma." Nature communications vol. 12,1 (2021): 7064. doi: https://doi.org/10.1038/s41467-021-27291-8
Zoumpoulidou G, Alvarez-Mendoza C, Mancusi C, Ahmed RM, Denman M, Steele CD, Tarabichi M, Roy E, Davies LR, Manji J, Cristalli C, Scotlandi K, Pillay N, Strauss SJ, Mittnacht S. Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma. Nat Commun. 2021 Dec 03;12(1):7064. doi: 10.1038/s41467-021-27291-8. PMID: 34862364; PMCID: PMC8642453.
Copy Download .nbib Format: NLM
Targeting CD99 Compromises the Oncogenic Effects of the Chimera EWS-FLI1 by Inducing Reexpression of Zyxin and Inhibition of GLI1 Activity.

Molecular cancer therapeutics

Balestra T, Manara MC, Laginestra MA, Pasello M, De Feo A, Bassi C, Guerzoni C, Landuzzi L, Lollini PL, Donati DM, Negrini M, Magnani M, Scotlandi K.
PMID: 34667115
Mol Cancer Ther. 2021 Oct 19; doi: 10.1158/1535-7163.MCT-21-0189. Epub 2021 Oct 19.

Ewing sarcoma, a highly aggressive pediatric tumor, is driven by EWS-FLI1, an oncogenic transcription factor that remodels the tumor genetic landscape. Epigenetic mechanisms play a pivotal role in Ewing sarcoma pathogenesis, and the therapeutic value of compounds targeting epigenetic...

Cite
Balestra T, Manara MC, Laginestra MA, et al. Targeting CD99 Compromises the Oncogenic Effects of the Chimera EWS-FLI1 by Inducing Reexpression of Zyxin and Inhibition of GLI1 Activity. Mol Cancer Ther. 2021;doi: 10.1158/1535-7163.MCT-21-0189.
Balestra, T., Manara, M. C., Laginestra, M. A., Pasello, M., De Feo, A., Bassi, C., Guerzoni, C., Landuzzi, L., Lollini, P. L., Donati, D. M., Negrini, M., Magnani, M., & Scotlandi, K. (2021). Targeting CD99 Compromises the Oncogenic Effects of the Chimera EWS-FLI1 by Inducing Reexpression of Zyxin and Inhibition of GLI1 Activity. Molecular cancer therapeutics, . https://doi.org/10.1158/1535-7163.MCT-21-0189
Balestra, Tommaso, et al. "Targeting CD99 Compromises the Oncogenic Effects of the Chimera EWS-FLI1 by Inducing Reexpression of Zyxin and Inhibition of GLI1 Activity." Molecular cancer therapeutics vol. (2021). doi: https://doi.org/10.1158/1535-7163.MCT-21-0189
Balestra T, Manara MC, Laginestra MA, Pasello M, De Feo A, Bassi C, Guerzoni C, Landuzzi L, Lollini PL, Donati DM, Negrini M, Magnani M, Scotlandi K. Targeting CD99 Compromises the Oncogenic Effects of the Chimera EWS-FLI1 by Inducing Reexpression of Zyxin and Inhibition of GLI1 Activity. Mol Cancer Ther. 2021 Oct 19; doi: 10.1158/1535-7163.MCT-21-0189. Epub 2021 Oct 19. PMID: 34667115.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 85 entries